Form 4: Kiora Pharmaceuticals Director Shapiro Acquires 3,000 Shares

Director Aron Shapiro indirectly acquired 3,000 shares of Kiora Pharmaceuticals through The Shapiro Family Irrevocable Trust on September 10, 2024.

Summary

• On September 10, 2024, Aron Shapiro, a director of Kiora Pharmaceuticals, indirectly acquired 3,000 shares of common stock.
• The shares were purchased at a price of $3.6 per share.
• The acquisition was made through The Shapiro Family Irrevocable Trust.
• Following the transaction, the Shapiro Family Irrevocable Trust beneficially owns 3,000 shares.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. It reflects a routine transaction by a director, which could be interpreted as a sign of confidence, but it's not a major event.

Positives

• A director's purchase of company stock can be seen as a positive signal, indicating confidence in the company's future prospects.

Industry Context

Form 4 filings are standard practice and provide transparency into the transactions of company insiders. These filings are closely watched by investors seeking insights into management's perspective on the company's valuation and future prospects.

Stakeholder Impact

• The transaction could have a minor positive impact on shareholder sentiment.

Key Dates

Keywords

Kiora Pharmaceuticals, Director, Share Acquisition, Form 4, Insider Trading, Beneficial Ownership, KPRX, Shapiro